Sheffield Teaching Hospitals NHS Foundation Trust has reached a significant milestone in the national Generation Study, recruiting its 2,000th participant at Jessop Wing Maternity Hospital as part of a pioneering effort to assess the future of newborn genetic screening.
The study, led by Genomics England in partnership with NHS England, is investigating whether whole genome sequencing at birth can identify more than 200 rare but treatable genetic conditions before symptoms develop. Nationally, the programme aims to recruit 100,000 newborn babies before the study concludes in spring 2027.
The achievement at Sheffield was made possible through the dedication of Generation Study volunteers, who engaged with more than 700 expectant families to help raise awareness and support recruitment.
Natalie Khoaz, Research Midwife and Principal Investigator for the study at Jessop Wing, said:
“The Generation Study is a hugely important national study which could shape the future of newborn screening. We are hugely proud to have hit our 2,000th participant milestone, which is a massive contribution to the study.
"Joining as a Generation Study site has been a tremendous honour, inspiring our teams to undertake more maternity research and demonstrating what can be achieved at a busy maternity hospital.
"It was also truly humbling to have played a key role in the detection of a rare eye cancer in little Freddie who was born here at Jessop Wing. Thanks to the study, his aggressive condition was detected when he was four weeks old, giving specialist doctors in Birmingham the best chance to minimise the impact on his vision.
“We would like to take this opportunity to thank all the families, staff and volunteers who have supported the Generation Study over the past two years.”
The Generation Study involves collecting a small blood sample from newborn babies, typically from the umbilical cord shortly after birth. The sample is then analysed using whole genome sequencing, enabling NHS scientists to identify genetic changes associated with more than 200 rare conditions included in the research programme.
When a potential condition is identified, families are contacted quickly and offered further NHS testing to confirm a diagnosis. Where appropriate, babies can then access specialist treatment and support at the earliest possible stage, potentially improving long-term health outcomes.
One of the study's most notable successes at Sheffield involved the early identification of a rare and aggressive eye cancer in a baby named Freddie. Detecting the condition when he was just four weeks old enabled specialist clinicians to begin intervention at the earliest opportunity, helping to reduce the potential impact on his sight.
Although the study is now entering its final phase, recruitment will continue at Jessop Wing on a more limited basis. Findings from the initiative could ultimately help shape the future of newborn screening programmes across the NHS, improving the speed at which rare genetic disorders are diagnosed and treated.
Image credit: iStock
